Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA

Lupus Science and Medicine

Volumn 3, Issue 1, 2016, Pages

  Collins, C E ^a   Dall'Era, M ^b   Kan, H ^c   Macahilig, C ^d   Molta, C ^c   Koscielny, V ^e   Chang, D J ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Medical Data Analytics   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Belimumab; Biologics; Real world effectiveness; Systemic Lupus Erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID;

ABNORMAL VALUE; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL OUTCOME; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNITED STATES;

EID: 84994069856     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000118     Document Type: Article

References (12)

1. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65.
2. GlaxoSmithKline. Belimumab prescribing information. http://us.gsk. com/products/assets/usbenlysta.pdf (accessed Jul 2015).
3. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
4. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthrits Rheum 2011;63:3918-30.
5. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-32.
6. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001;10:140-7.
7. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
8. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
9. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10: 413-24.
10. Dooley M, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22:63-72.
11. GlaxoSmithKline. Belimumab assessment of safety in SLE (BASE). Study synopsis. https://clinicaltrials.gov/ct2/show/NCT01705977 (accessed Jul 2015).
12. GlaxoSmithKline. Safety and effectiveness of belimumab in system lupus erythematosus registry (SABLE). Study synopsis. https:// clinicaltrials.gov/ct2/show/NCT01729455 (accessed Jul 2015).